Safety of TCMCB07, a melanocortin‐4 antagonist peptide, in dogs with naturally occurring cachexia

Autor: Sandra M. Axiak‐Bechtel, Stacey B. Leach, Jessica R. Newton‐Northup, Rowan J. Milner, Stacey A. Fox‐Alvarez, Lana I. Fagman, Kaylee A. Young, Deborah J. Tate, Zachary M. Wright, John D. Chretin, Justin W. Allen, Sean K. Yoshimoto, Kimberly A. Selting, Brian K. Flesner, Carrie R. White, Tracy Mills, Michael Aherne, Philip J. Bergman, LeAnn Qi, Kenneth A. Gruber, Michael F. Callahan
Jazyk: angličtina
Rok vydání: 2023
Předmět:
Zdroj: Journal of Veterinary Internal Medicine, Vol 37, Iss 6, Pp 2344-2355 (2023)
Druh dokumentu: article
ISSN: 1939-1676
0891-6640
DOI: 10.1111/jvim.16915
Popis: Abstract Background The melanocortin 4 antagonist TCMCB07 is safe and effective in reversing cachexia caused by sepsis or cancer in rodents. The safety and pharmacokinetics of TCMCB07 are demonstrated in healthy beagle dogs. Hypothesis/Objectives The objectives of this study were to investigate the safety, peak plasma concentrations, and potential for efficacy of TCMCB07 in pet dogs with naturally occurring cachexia over a 4‐week time period. Animals Fourteen dogs with cachexia of any underlying cause, except cancer of the oral cavity or gastrointestinal tract, were eligible for enrollment with informed client consent. Methods This study was a prospective, 1‐armed open‐label trial. Physical examination, complete blood count, chemistry panel, and owner‐assessed quality of life surveys were checked at weeks 1, 2, and 4. Due to potential for bradycardia and hypotension, Holter monitoring and blood pressure evaluations were scheduled at pre‐enrollment and week 4. Results Fourteen dogs completed the trial. Significant changes detected included increased mean body weight (18.6‐19.5 kg, P
Databáze: Directory of Open Access Journals
Externí odkaz: